Indantadol

Indantadol

Indantadol
Systematic (IUPAC) name
N-(2,3-dihydro-1H-inden-2-yl)glycinamide
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number
ATC code None
ChemSpider
UNII  YesY
Chemical data
Formula C11H14N2O 
Mol. mass 190.24 g/mol

Indantadol (CHF-3381, V-3381) is a drug which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi.[1][2][3][4][5][6][7][8] It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor,[5][6][9] and as a low affinity, non-competitive NMDA receptor antagonist.[1][2][10] A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.[7][8][11][12]

See also

References

  1. ^ a b Villetti G, Bregola G, Bassani F, et al. (June 2001). "Preclinical evaluation of CHF3381 as a novel antiepileptic agent". Neuropharmacology 40 (7): 866–78.  
  2. ^ a b Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). "Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms". Pharmacology, Biochemistry, and Behavior 70 (1): 157–66.  
  3. ^ Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). "Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist". Neuroreport 13 (16): 2071–4.  
  4. ^ Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). "Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14.  
  5. ^ a b "CHF 3381". Drugs in R&D 5 (1): 28–30. 2004.  
  6. ^ a b Mattia C, Coluzzi F (September 2007). "Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain". IDrugs : the Investigational Drugs Journal 10 (9): 636–44.  
  7. ^ a b "IN-STEP Phase IIb study results". 
  8. ^ a b "Vernalis initiates Pilot Study of V3381 in patients with chronic cough". 
  9. ^ Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). "CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model". The Journal of Pain 7 (8): 565–74.  
  10. ^ Barbieri M, Bregola G, Buzzi A, et al. (August 2003). "Mechanisms of action of CHF3381 in the forebrain". British Journal of Pharmacology 139 (7): 1333–41.  
  11. ^ "V3381CC". 
  12. ^ "Vernalis completes recruitment in V3381 Phase II IN-STEP study for neuropathic pain".